INTRODUCTION
Conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), such as methotrexate, hydroxychloroquine, and sulfasalazine, have long been the mainstay of treatment for RA, and their initiation in the early stages of disease can curb or halt the progressive synovitis and joint destruction, thereby limiting disability [1] [2] [3] . However, an improved understanding of the pathogenesis of RA over the past decade has led to the development of several biological DMARDs (bDMARDs) that directly target components of the RA inflammatory cascade, and have transformed the management of this disease [3] . The first targeted bDMARD for RA was the tumor necrosis factor (TNF)-antagonist, etanercept (Enbrel Ò ), which was approved by the US Food and Drug Administration in 1998 [4] . Since then, a number of other bDMARDs have been approved and are now commercially available; many of these treatments are administered by subcutaneous (SC) injection, with a number of presentations and devices currently being available (prefilled syringes, vial and syringe, and autoinjector devices). A number of studies have reported that patients with RA prefer autoinjector devices over conventional methods of treatment administration, with patients citing such factors as these devices being easier to use, more convenient, more acceptable, less painful, and less time-consuming [5] [6] [7] . Although bDMARDs are effective in reducing RA symptoms, slowing disease progression, and improving physical function and quality of life [3, [8] [9] [10] , they are costly [11] . Consequently, in many countries, not all patients who may be eligible for treatment with biological drugs according to guidelines are prescribed these drugs, with preference generally being given to those with more severe and aggressive disease [12] . Indeed, results from a cross-sectional study estimated that, in total, 320 million people in the European region (approximately 40%) have severely restricted access to bDMARDs in cases of RA, with barriers to access primarily being financial and administrative [11] . However, the patent expiry of some of these bDMARDs has enabled the introduction of therapeutically similar, and more affordable, alternativesknown as biosimilars [13] . To be eligible to participate in the survey, patients had to have been diagnosed with moderate or severe RA by a physician and had to be using the Enbrel MYCLIC autoinjector for at least 1 month at the time of recruitment into the survey. There were no specific exclusion criteria for this survey. Patients provided written consent before participating in the survey and were compensated for their time with an honorarium.
Questionnaire Design
The survey was developed in a two-stage process, with the guidance on the interview questions and process taken from a recent survey in patients with relapsing-remitting multiple sclerosis, which investigated patients' perceptions of the importance of different general attributes of autoinjectors [18] .
Initially, an English structured quantitative master questionnaire was created, which was then tested and validated in pilot interviews (n = 4) to ensure appropriate content, flow, and clarity of the survey. During these pilot interviews, respondents were asked to provide those autoinjector attributes that they considered to be the most important for inclusion in the main quantitative survey.
These interviews were also used to determine whether respondents fully understood the instructions provided with the questionnaire.
The final version of the English questionnaire was then translated into four languages The questionnaire was broadly divided into four sections. In the first section (Q1), patients were asked to rate the importance of ten attributes, when using an autoinjector device in general for self-injection of their RA treatment, on a seven-point scale (1 = not important at all; 7 = extremely important).
The following attributes were assessed: (1) size of the autoinjector, (2) attractive design of the autoinjector, (3) easy to grip the autoinjector, (4) easy to operate the self-injection with the autoinjector, (5) audible feedback after treatment has been successfully injected, (6) visual feedback after treatment has been successfully injected, (7) concealing the injection needle in the injector body, (8) intuitive/self-explaining usage, (9) button-free autoinjector, and (10) 
Data Analysis
The analysis population included all patients who completed the survey. During the face-to-face interviews, patient responses were recorded by the interviewer and data input from all interviews was collected by the recruitment agency (Schmiedl Marktforschung GmbH 
RESULTS

Patient Characteristics
A total of 220 patients from France (n = 30), Germany (n = 65), Italy (n = 67), Spain (n = 12), and the UK (n = 46) participated in this survey.
The lower number from Spain was due to the lower availability of patients with the required experience in using the Enbrel MYCLIC autoinjector. The majority of patients were female (72%) and aged 51-60 years (36%) ( Table 1 ). All patients participating in the survey were using the Enbrel MYCLIC autoinjector.
Importance of Attributes when Using
an Autoinjector Device for Self-injection
Patients were asked to evaluate the importance of ten attributes, when using an autoinjector device in general for self-injection of their RA medication, on a seven-point scale (1 = not important at all; 7 = extremely important).
Overall, 'easy to operate the self-injection' was ranked as the most important attribute by patients (mean score of 6. 
Patient Preferences for Autoinjector Based on Attributes Assessed
Patients were asked for their preference of autoinjector based on nine of the ten attributes previously assessed ('button-free device' was not included in this section).
Overall, the attribute of 'easier to operate' was a strong differentiator for the Benepali autoinjector compared to the Enbrel MYCLIC autoinjector, with 78% of patients reporting that the Benepali autoinjector was 'easier to operate' than the Enbrel MYCLIC autoinjector (Fig. 2) . Furthermore, country-specific data showed that patients from all five EU countries preferred the Benepali autoinjector (Fig. 3) .
Overall, patients preferred the Benepali autoinjector compared to the Enbrel MYCLIC autoinjector for attributes of 'easier to grip', Fig. 1 Importance of attributes when using an autoinjector device for self-injection, as assessed by patients (mean scores on a scale of 1-7; 1 = not important at all; 7 = extremely important)
Fig. 2 Patient preference for the Benepali versus Enbrel autoinjectors based on attributes assessed
'more intuitive to use', 'better visual feedback', 'right weight', 'better size', and 'attractive design' (Fig. 2) . The attribute of 'conceals the injection needle better' was rated as being the same for both autoinjectors by 72% of patients.
Patient Preference for Autoinjector and Attributes that Drive Patient Choice of Autoinjector
Patients were asked their opinion as to which autoinjector they would prefer to use for reporting a preference for the Enbrel MYCLIC autoinjector. In addition, 29 patients (13%) stated that they had no preference for either device. A preference for the Benepali autoinjector was also reported across all five EU countries (Fig. 4) .
Patients were also asked to select the top three attributes that drove their preference for one autoinjector over the other. Of the 163 patients who preferred the Benepali autoinjector, the reasons most commonly given were 'easy to operate the self-injection' (n = 117), followed by 'button-free autoinjector' (n = 110). Of the 29 patients who preferred the Enbrel MYCLIC autoinjector, the most common reasons given were 'easy to operate' (n = 26), and 'intuitive/self-explaining usage' (n = 17) (Fig. 5) .
DISCUSSION
Results from this patient survey (n = 220) conducted in five countries in the EU reported that the majority of patients (74%) who were using the Enbrel MYCLIC autoinjector preferred the Benepali autoinjector to the Enbrel MYCLIC autoinjector for self-injection of their RA medication. These results were closely aligned with those of the recently reported nurse survey Country-specific data (n = 149), which was based on the same protocol, and reported that 86% of nurses felt that their patients would prefer the Benepali autoinjector [17] .
Overall, attributes of 'easy to operate the self-injection', 'easy to grip', and 'intuitive/self-explaining usage' were considered by patients as being the most important attributes when using an autoinjector to manage their RA. This was consistent with the results from the nurse survey, in which these three attributes were also considered by nurses as being the most important attributes when selecting an autoinjector for their patients with RA [17] . In line with the nurse survey, patients rated the attribute of 'easy to operate the self-injection' as a strong differentiator for the Benepali autoinjector compared to the Enbrel MYCLIC autoinjector in this survey. However, the attribute of 'intuitive/self-explaining usage', which nurses reported as a strong and 'button-free autoinjector' were reported as key drivers impacting patients' choice of autoinjector. Once again, these results were identical to those reported from the nurse survey, in which these two attributes were also reported as being key drivers impacting nurses' choice of autoinjector [17] . Altogether, the attributes of the Benepali autoinjector that patients most preferred, which were in alignment with results from the nurse survey [17] , can be described as those that make the handling process easier for the patient, suggesting that both patients and nurses in
Europe consider the Benepali autoinjector to be easier to handle than the Enbrel MYCLIC autoinjector. This is of paramount importance, as many patients with RA suffer from compromised dexterity, which can affect the ability to perform the steps required [20] .
Adherence to biological therapy is essential for sustaining long-term efficacy and optimizing therapeutic outcomes in patients with RA. However, adherence to the therapeutic regimen has been reported as low (varying from 30 to 80%), with the route of administration being an important factor in treatment adherence [21, 22] 
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